Benefits of erythropoietin in renal transplantation

Transplantation

Volumn 79, Issue 3 SUPPL., 2005, Pages

  Choukroun, Gabriel ^a   Martinez, Frank ^b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; APOPTOSIS INHIBITOR; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; PROTEIN KINASE B; PROTEIN SYNTHESIS INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE DISMUTASE;

ANEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT FAILURE; GRAFT SURVIVAL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SECONDARY HYPERPARATHYROIDISM; SODIUM RETENTION;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY TRANSPLANTATION; PREVALENCE;

EID: 14344252096     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000153304.39865.6E     Document Type: Conference Paper

References (12)

1. Vanrenterghen Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3: 835.
2. Kim HC, Park SB, Han SY, Whang EA. Anemia following renal transplantation. Transplant Proc 2003; 35: 302.
3. Rigatto C, Foley R, Jeffery J, et al. Electrocardiographs left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462.
4. Kean WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 4: 1499.
5. McDougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489.
6. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996; 50: 1373.
7. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307.
8. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure. J Am Soc Nephrol 2003; 14: S173.
9. Yang CW, C Li, JY Jung, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. Faseb J 2003; 12: 1754.
10. Digicaylioglu M, SA Lipton. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascades. Nature 2001; 412: 641-647.
11. Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 1994; 5: 1216.
12. Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17: 1667.